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The expression patterns of 62 genes interacting with p53 have been investigated in 24 normal and cancerous tissues using NIH's dbEST
library. The expression levels of individual genes, such as the TTP53 gene itself, but also other genes, vary up to 33-fold among the 24 different
tissues and no consistent pattern can be recognized. However, when expression levels for all 63 genes are summed, these “cumulated levels” are
surprisingly constant over the 24 investigated normal tissues. In cancers, the variation is further reduced. Essentially, the cumulated expression
levels in cancer are independent of those in normal tissue. We furthermore constructed a linear statistical classifier, i.e., a weighted sum of gene
expression levels, which robustly distinguishes normal from cancer tissue independent of the particular kind of tissue. Thus, despite very large
differences for individual genes and considerable changes during carcinogenesis, the cumulated expressions have narrowly defined levels.
© 2007 Elsevier Inc. All rights reserved.Keywords: Data mining; dbEST database; Cancer genes; Statistical classifierA defect in only one gene as a cause of disease is rather an
exception than the rule. On the other hand, though it may be
envisioned for the future, at the present state of knowledge it
appears impossible to understand disease as a complete inter-
action network of some 10,000 genes in a cell. What appears
more reasonable is the attempt to find ensembles of genes that
cooperate in the genesis of disease and to understand them as
functional units. If such an ensemble remains unaffected during
the progress of disease it may be ruled out as a driving force of
the latter. Particularly interesting is carcinogenesis. When an
ensemble of genes behaves similarly (for example is over- or
underexpressed as a whole) in a wide variety of cancer tissues,
compared to their normal counterparts, it may be seen as a
general feature of cancer and does not contribute to the genesis
of just one or a few selected cancers. Alternatively, when such
an ensemble of genes behaves differently in a wide variety of⁎ Corresponding author. Fax: +49 3641 656410.
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doi:10.1016/j.ygeno.2007.06.005normal tissues but more similarly in the corresponding cancer
tissues, this suggests functional relevance,
Indeed a few such ensembles of genes, namely a few
classical biochemical pathways, are accepted as acting as a
whole. For example, glycolysis is elevated in most cancers
(the Warburg effect [1]) and has recently gained new interest
[2]. Almost all the genes in the glycolysis pathway are
overexpressed in a wide variety of phenotypically very
different cancer tissues [3]. In addition to these more classical
functional ensembles of genes others may be envisioned, for
example, nodes in interaction networks [4]. Other ensembles
may be those that are differentially sensitive (noisy) toward
external stimuli. The expression of housekeeping genes does
not reveal such sensitivity, while genes involved in environ-
mental responses do so [5]. Also, ensembles of genes have
been discovered that usually are expressed only in one given
healthy tissue but also are group-wise switched on in cancers
of another tissue, in whose normal counterpart they are not
expressed [6]. As already mentioned above, particularly
interesting are markers that indicate cancer in general, i.e.,
which are over- or underexpressed in a wide variety of cancers
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[8].
In human cells, one of the best known candidates for such a
functional ensemble of cooperating genes is the tumor
suppressor TP53 and 62 of its interacting proteins. The product
of this gene is located at the intersection between several
pathways involved in carcinogenesis. Together with 62 other
proteins of four pathways, TP53 has a central function in the
regulation of the cell cycle and apoptosis [9,10]. Vast amounts
of data on its expression and mutations in cancer are available
(for example [10–12]), but many effects are ascribed solely to
this gene and its product. It is, however, also known that
molecules up- and downstream in the signaling cascade of
TP53 also contribute to transforming a cell into a neoplastic
phenotype. Studies on TP53 as an ensemble with its binding
proteins are rare [10,13] and, particularly, direct comparisons of
a wide variety of phenotypically very different tissues and their
cancers are still missing.
We have performed an in silico study on the expression of 62
TP53-binding genes and TP53 itself in 24 different healthy
tissues that represent approximately 70% of all clinical cases [3]
and their corresponding cancer tissues. There is some discus-
sion on the genes that should be ascribed to this pathway. We
have used genes listed in TP53-dependent pathways by the
Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.
genome.jp/kegg) (see also Materials and methods). Omitting
one or a few genes will probably not seriously affect the
statements made in the following.
In silico studies have become possible since a vast amount of
gene expression data is now available. The NIH provides aFig. 1. Expression of the TP53 gene in 24 tissues and the corresponding cancers. For n
factor of 33. Also, in cancer some expression levels are increased, some of them are re
A similar observation is made for other genes such as STAT1, CDKN1A, or SHC1.database (dbEST) that collects and normalizes gene expression
data, published in the literature, and offers such collected data
for a large number of annotated genes [14]. We used this
database [15–18] to get an overview on the expression behavior
of genes of TP53-related genes [19].
Currently it is not possible to allow discrimination of cancer
subclasses or tumor stages or ethnic variability. The dbEST
database simply does not provide such data for all 24
investigated cancers. However, a major result of the present
study will be that cancers with very different phenotypes are
surprisingly uniform and thus the lack of fine distinction
probably does not invalidate the general message of the present
work. In other words, the aim of the present study is to provide a
crude grid of the roles of 63 genes in 24 cancers, i.e., 3024 data
points. This grid, as soon as more detailed studies are available
in literature, may then become a sort of guideline to characterize
subclasses of different cancers and specific aspects of individual
patients.
Results
Table 1 gives the expression data, i.e., the aji, for the 63
genes in 24 different healthy and cancerous tissues as they can
be derived from data such as in Table 3 under Materials and
methods, multiplied by 100 as will be mentioned there. Below
each of the two blocks for normal tissue and cancer in Table 1
the sums of the expression levels of the all genes in a specific
cancer are given.
Fig. 1 shows the expression levels for the TP53 gene in 24
selected tissues and the corresponding cancers. For tissues forormal nervous tissue, the level is 0.033, for liver it is 0.001, i.e., the variation is a
duced, i.e., no consistent pattern emerges when only this single gene is regarded.
Table 1
Expression data for the 63 p53-signaling genes in 24 different cancers (raw data obtained via tables of the type of Table 3 multiplied by 100 for easier reading)
Gene name Description Cytogenetic
location
Bone Bone
marrow
Brain Cartilage Cervix Colon Eye Head and
neck
Kidney Liver Lung Lymph
node
Lympho-
reticular
Mammary
gland
Muscle Nervous
tissue
Ovary Pancreas Placenta Prostate Skin Stomach Testis Uterus
(A) Normal
AATF Apoptosis
antagonizing
transcription
factor
17q11.2-q12 0.000 0.000 0.008 0.007 0.000 0.000 0.011 0.004 0.006 0.006 0.006 0.009 0.006 0.005 0.015 0.001 0.000 0.000 0.006 0.008 0.002 0.004 0.023 0.003
APAF1 Apoptotic peptidase
activating factor
12q23 0.000 0.006 0.001 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.001 0.006 0.000 0.002 0.005 0.002 0.000 0.000 0.001 0.000 0.000 0.000 0.001 0.000
ATM Ataxia
telangiectasia
mutated
11q22-q23 0.007 0.000 0.004 0.007 0.000 0.000 0.007 0.016 0.005 0.006 0.003 0.037 0.000 0.015 0.013 0.004 0.000 0.000 0.004 0.004 0.002 0.004 0.007 0.008
ATR Ataxia telangiectasia
and Rad3 related
3q22-q24 0.000 0.000 0.003 0.000 0.000 0.000 0.002 0.002 0.003 0.006 0.003 0.015 0.000 0.004 0.006 0.001 0.017 0.027 0.002 0.001 0.004 0.004 0.006 0.005
Bak1 BCL2-antagonist/
killer 1
6p21.3 0.000 0.000 0.001 0.000 0.000 0.004 0.002 0.000 0.002 0.001 0.005 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.000 0.004 0.004 0.001 0.000
BAX BCL2-
associated X
protein
19q13.3-q13.4 0.000 0.006 0.000 0.000 0.000 0.004 0.003 0.000 0.000 0.000 0.002 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.001 0.000 0.007 0.001 0.000
BCL2 B-cell CLL/lymphoma 2 18q21.33|18q21.3 0.000 0.013 0.003 0.000 0.000 0.011 0.001 0.004 0.008 0.002 0.005 0.001 0.000 0.020 0.006 0.001 0.000 0.000 0.018 0.005 0.013 0.032 0.005 0.003
BID BH3 interacting domain
death agonist
22q11.1 0.000 0.000 0.004 0.000 0.000 0.000 0.005 0.000 0.002 0.000 0.003 0.004 0.000 0.002 0.000 0.005 0.000 0.000 0.001 0.008 0.006 0.000 0.001 0.010
BRCA1 Breast cancer 1,
early onset
17q21 0.007 0.013 0.001 0.000 0.000 0.004 0.001 0.000 0.001 0.002 0.001 0.021 0.000 0.004 0.002 0.002 0.009 0.000 0.000 0.001 0.000 0.000 0.002 0.000
BRCA2 Breast cancer 2,
early onset
13q12.3 0.000 0.000 0.000 0.000 0.000 0.004 0.001 0.002 0.000 0.003 0.002 0.013 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.003 0.000
CASP2 Caspase 2 7q34-q35 0.000 0.000 0.001 0.000 0.000 0.004 0.006 0.000 0.002 0.003 0.001 0.030 0.000 0.004 0.002 0.006 0.000 0.000 0.006 0.005 0.006 0.004 0.002 0.000
CASP9 Caspase 9 1p36.3-p36.1 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.005 0.003 0.001 0.004 0.000 0.002 0.000 0.001 0.009 0.000 0.005 0.002 0.002 0.000 0.005 0.018
CCNE2 Cyclin E2 8q22.1 0.000 0.006 0.003 0.000 0.000 0.000 0.000 0.000 0.002 0.003 0.000 0.013 0.000 0.002 0.005 0.001 0.000 0.000 0.002 0.000 0.000 0.000 0.004 0.000
CCNG1 Cyclin G1 5q32-q34 0.000 0.019 0.013 0.020 0.000 0.007 0.028 0.013 0.019 0.007 0.009 0.009 0.000 0.005 0.010 0.013 0.000 0.000 0.004 0.008 0.034 0.014 0.004 0.018
CCNG2 Cyclin G2 4q21.1 0.000 0.006 0.006 0.013 0.000 0.004 0.006 0.002 0.005 0.000 0.006 0.012 0.000 0.013 0.005 0.013 0.000 0.000 0.005 0.007 0.004 0.000 0.001 0.005
CDC14A CDC14 cell divis.
cycle 14 homolog A
1p21 0.007 0.000 0.001 0.000 0.000 0.004 0.002 0.000 0.001 0.002 0.003 0.004 0.000 0.002 0.002 0.003 0.000 0.000 0.001 0.004 0.000 0.004 0.010 0.000
CDC2 Cell division cycle 2,
G1 to S and G2 to M
10q21.1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.003 0.006 0.005 0.052 0.006 0.002 0.006 0.001 0.000 0.000 0.000 0.000 0.004 0.000 0.006 0.000
CDC25A Cell division cycle 25A 3p21 0.000 0.000 0.001 0.000 0.000 0.000 0.002 0.000 0.002 0.000 0.001 0.001 0.000 0.002 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
CDC25C Cell division cycle 25C 5q31 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.001 0.000 0.006 0.006 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.007 0.000
CDK4 Cyclin-dependent
kinase 4
12q14 0.015 0.000 0.004 0.000 0.000 0.004 0.015 0.000 0.012 0.003 0.007 0.016 0.000 0.002 0.002 0.007 0.000 0.000 0.011 0.008 0.011 0.004 0.001 0.008
CDK7 Cyclin-dependent
kinase 7
5q12.1 0.000 0.006 0.003 0.000 0.000 0.004 0.002 0.004 0.005 0.006 0.005 0.009 0.000 0.004 0.002 0.005 0.000 0.000 0.005 0.005 0.000 0.000 0.006 0.008
CDKN1A/
P21
Cyclin-dep. kinase
inhibitor 1A (p21, Cip1)
6p21.2 0.058 0.019 0.011 0.079 0.000 0.032 0.015 0.027 0.004 0.003 0.037 0.000 0.000 0.020 0.010 0.004 0.009 0.013 0.017 0.014 0.076 0.021 0.004 0.013
CDKN2A interleukin 6
(interferon, beta 2)
9p21 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.000 0.000 0.003 0.001 0.003 0.011 0.002 0.001 0.001 0.000 0.000 0.003 0.000 0.000 0.000 0.003 0.000
CHEK1 CHK1 checkpoint
homolog (S. pombe)
11q24-q24 0.022 0.000 0.001 0.000 0.000 0.000 0.001 0.002 0.002 0.003 0.001 0.006 0.000 0.000 0.002 0.001 0.009 0.000 0.002 0.001 0.007 0.000 0.007 0.000
CHEK2/
RAD53
CHK2 checkpoint
homolog (S. pombe)
22q11|22q12.1 0.000 0.000 0.000 0.000 0.000 0.004 0.005 0.000 0.001 0.003 0.002 0.006 0.000 0.000 0.001 0.004 0.009 0.000 0.003 0.001 0.000 0.000 0.003 0.000
CSPG2/
VCAN
Versican 5q14.3 0.022 0.026 0.013 0.020 0.000 0.018 0.000 0.000 0.006 0.006 0.014 0.000 0.000 0.007 0.020 0.013 0.034 0.000 0.016 0.008 0.013 0.000 0.003 0.031
CX3CL1 Chemokine
(C-X3-C motif)
ligand 1
16q13 0.000 0.000 0.007 0.000 0.000 0.000 0.007 0.002 0.002 0.005 0.011 0.000 0.000 0.015 0.001 0.019 0.000 0.000 0.002 0.006 0.002 0.000 0.001 0.000
(continued on next page)
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Table 1 (continued)
Gene name Description Cytogenetic
location
Bone Bone
marrow
Brain Cartilage Cervix Colon Eye Head and
neck
Kidney Liver Lung Lymph
node
Lympho-
reticular
Mammary
gland
Muscle Nervous
tissue
Ovary Pancreas Placenta Prostate Skin Stomach Testis Uterus
DAPK1 Death-associated protein
kinase 1
9q34.1 0.000 0.000 0.002 0.000 0.000 0.007 0.006 0.002 0.001 0.004 0.007 0.000 0.000 0.011 0.012 0.008 0.009 0.013 0.044 0.001 0.009 0.000 0.001 0.003
DAXX Death-associated
protein 6
6p21.3 0.015 0.013 0.001 0.013 0.000 0.004 0.013 0.020 0.002 0.003 0.005 0.006 0.011 0.020 0.005 0.003 0.000 0.000 0.002 0.001 0.007 0.004 0.010 0.005
DDR1 Discoidin domain rec.
family, member 1
6p21.3 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.002 0.000 0.000 0.000 0.013 0.001 0.000 0.000 0.000 0.000 0.000
E2F1 APBA2BP, amyloid
beta (A4) precursor
20q11.22 0.022 0.019 0.007 0.007 0.000 0.004 0.008 0.002 0.005 0.002 0.004 0.006 0.006 0.000 0.006 0.015 0.009 0.000 0.004 0.007 0.007 0.000 0.005 0.005
E2F3 E2F transcription
factor 3
6p22 0.000 0.006 0.002 0.007 0.000 0.000 0.002 0.002 0.002 0.006 0.003 0.004 0.000 0.002 0.004 0.001 0.000 0.000 0.001 0.002 0.002 0.000 0.003 0.000
ERK/
EPHB2
EPHB2, EPH
receptor B2
1p36.1-p35 0.000 0.000 0.001 0.000 0.000 0.021 0.013 0.000 0.001 0.000 0.004 0.000 0.000 0.000 0.004 0.003 0.000 0.000 0.004 0.000 0.000 0.000 0.003 0.000
FADD Fas (TNFRSF6)-assoc.
via death domain
11q13.3 0.000 0.000 0.003 0.000 0.000 0.004 0.009 0.000 0.004 0.002 0.004 0.000 0.000 0.000 0.001 0.003 0.009 0.000 0.008 0.001 0.011 0.000 0.002 0.000
FANCA Fanconi anemia,
complementation
group A
16q24.3 0.000 0.000 0.001 0.000 0.000 0.011 0.002 0.000 0.001 0.010 0.001 0.027 0.011 0.000 0.002 0.003 0.017 0.000 0.004 0.000 0.000 0.007 0.005 0.005
GADD45A Growth arrest/
DNA-damage-inducible
1p31.2-p31.1 0.000 0.000 0.001 0.013 0.028 0.000 0.006 0.000 0.015 0.004 0.003 0.001 0.000 0.002 0.000 0.004 0.009 0.000 0.003 0.002 0.007 0.000 0.000 0.016
HDAC1 Histone deacetylase 1 1p34 0.015 0.006 0.005 0.007 0.000 0.018 0.013 0.024 0.008 0.006 0.012 0.021 0.061 0.004 0.004 0.002 0.034 0.000 0.008 0.008 0.006 0.007 0.004 0.005
IL6 Interleukin 6
(interferon, beta 2)
7p21 0.022 0.000 0.000 0.000 0.000 0.000 0.005 0.000 0.002 0.000 0.004 0.001 0.006 0.000 0.001 0.000 0.017 0.000 0.002 0.000 0.011 0.000 0.000 0.000
JUN V-jun sarc. virus 17
oncogene homolog
1p32-p31 0.029 0.019 0.007 0.007 0.000 0.021 0.020 0.009 0.011 0.004 0.010 0.006 0.000 0.035 0.004 0.016 0.017 0.000 0.013 0.019 0.011 0.004 0.007 0.044
KRAS V-Ki-ras2 rat sarc.
oncogene homolog
12p12.1 0.000 0.006 0.003 0.000 0.000 0.000 0.001 0.002 0.004 0.002 0.004 0.038 0.000 0.002 0.005 0.009 0.009 0.000 0.008 0.001 0.013 0.000 0.003 0.000
LIG4 Ligase IV, DNA,
ATP-dependent
13q33-q34 0.000 0.000 0.004 0.000 0.000 0.000 0.001 0.000 0.000 0.004 0.000 0.003 0.000 0.000 0.007 0.003 0.000 0.000 0.001 0.001 0.004 0.018 0.000 0.000
MDM2 Mdm2/p53 binding
protein
12q14.3-q15 0.000 0.000 0.000 0.000 0.000 0.004 0.000 0.000 0.001 0.000 0.004 0.009 0.000 0.002 0.005 0.000 0.000 0.000 0.003 0.002 0.000 0.000 0.001 0.000
MDM4 Mdm4/p53 binding
protein
1q32 0.007 0.000 0.004 0.000 0.000 0.007 0.006 0.007 0.004 0.003 0.007 0.016 0.006 0.015 0.009 0.005 0.009 0.000 0.005 0.006 0.000 0.014 0.008 0.013
MSH2 MutS homolog 2
nonpolyposis type 1
2p22-p21 0.000 0.000 0.007 0.000 0.000 0.000 0.001 0.004 0.006 0.001 0.003 0.010 0.017 0.000 0.002 0.013 0.000 0.000 0.001 0.000 0.006 0.004 0.007 0.000
MYC V-myc
myelocytomatosis
homolog
8q24.12-q24.13 0.000 0.000 0.007 0.026 0.000 0.004 0.001 0.002 0.005 0.004 0.002 0.000 0.000 0.009 0.004 0.008 0.000 0.000 0.004 0.005 0.011 0.004 0.001 0.008
P300/
EP300
EP300, E1A binding
protein p300
22q13.2 0.000 0.000 0.002 0.000 0.000 0.004 0.002 0.004 0.002 0.002 0.008 0.025 0.000 0.007 0.000 0.005 0.000 0.000 0.011 0.004 0.006 0.007 0.006 0.005
P38/
MAPK1
MAPK1, Mitogen-
activated prot.
Kinase 1
22q11.2|22q11.21 0.007 0.006 0.041 0.013 0.000 0.004 0.016 0.009 0.014 0.007 0.011 0.034 0.000 0.025 0.010 0.035 0.000 0.000 0.007 0.007 0.035 0.011 0.013 0.031
PCAF P300/CBP-associated
factor
3p24 0.000 0.006 0.005 0.000 0.000 0.000 0.005 0.004 0.002 0.005 0.005 0.006 0.000 0.002 0.005 0.001 0.009 0.000 0.021 0.005 0.004 0.004 0.002 0.003
RB1 Retinoblastoma 1 13q14.2 0.000 0.000 0.004 0.000 0.000 0.000 0.002 0.004 0.004 0.007 0.002 0.030 0.000 0.004 0.007 0.003 0.009 0.000 0.007 0.000 0.007 0.018 0.008 0.008
REF3L REV3-like, catal. subun.
of DNA pol zeta
6q21 0.000 0.000 0.003 0.007 0.000 0.004 0.009 0.000 0.003 0.006 0.005 0.010 0.006 0.005 0.016 0.006 0.009 0.000 0.006 0.007 0.002 0.004 0.004 0.018
SHC1 SHC (Src homol. 2
transforming prot. 1
1q21 0.007 0.013 0.020 0.053 0.000 0.007 0.008 0.011 0.039 0.006 0.014 0.007 0.039 0.004 0.013 0.007 0.017 0.000 0.014 0.025 0.061 0.004 0.006 0.008
SIRT1 Sirtuin 1 10q21.3 0.015 0.000 0.002 0.000 0.000 0.004 0.002 0.000 0.001 0.004 0.002 0.007 0.006 0.004 0.002 0.000 0.000 0.000 0.002 0.001 0.004 0.000 0.004 0.010
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STAT1 Sign. Transduc.+activ.
of transcript. 1
2q32.2 0.029 0.013 0.017 0.073 0.000 0.007 0.014 0.004 0.008 0.014 0.010 0.013 0.000 0.015 0.006 0.009 0.000 0.000 0.011 0.012 0.013 0.018 0.010 0.016
STAT5A Sign. Transduc.+activ.
of transcript.5A
17q11.2 0.015 0.000 0.001 0.007 0.000 0.004 0.007 0.002 0.003 0.004 0.005 0.004 0.022 0.005 0.002 0.002 0.017 0.000 0.004 0.005 0.006 0.004 0.001 0.005
TNF TNF (superfamily,
member 2)
6p21.3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.007 0.000 0.000 0.000 0.000 0.009 0.000 0.002 0.001 0.000 0.000 0.001 0.000
TP53 Tumor protein p53
(Li-Fraumeni)
17p13.1 0.000 0.000 0.014 0.033 0.028 0.011 0.002 0.002 0.003 0.001 0.008 0.006 0.000 0.029 0.001 0.006 0.017 0.000 0.004 0.013 0.009 0.032 0.010 0.000
TP53BP2 Tumor protein p53
binding protein, 2
1q42.1 0.000 0.000 0.019 0.007 0.000 0.004 0.006 0.007 0.006 0.001 0.002 0.003 0.000 0.009 0.002 0.005 0.000 0.000 0.004 0.007 0.006 0.000 0.001 0.003
TP73 Tumor protein p73 1p36.3 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.000 0.006 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.001 0.000
TP73L TP73L, Tumor protein
p73-like
3q28 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.000 0.000 0.002 0.000 0.000 0.000 0.007 0.000 0.000 0.000 0.002 0.010 0.011 0.000 0.001 0.000
TRADD TNFRSF1A-associated
via death domain
16q22 0.000 0.000 0.001 0.000 0.000 0.004 0.002 0.000 0.009 0.003 0.002 0.015 0.006 0.002 0.000 0.000 0.000 0.000 0.001 0.008 0.004 0.000 0.001 0.003
WRN Werner syndrome 8p12-p11.2 0.000 0.000 0.001 0.000 0.000 0.000 0.004 0.000 0.000 0.006 0.002 0.006 0.000 0.000 0.004 0.000 0.000 0.000 0.001 0.001 0.000 0.004 0.001 0.003
WT1 Wilms tumor 1 11p13 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.015 0.023
XRCC4 XRCC4 DNA
repair protein
5q13-q14 0.000 0.000 0.001 0.007 0.000 0.000 0.002 0.002 0.003 0.001 0.000 0.003 0.000 0.004 0.002 0.002 0.000 0.000 0.002 0.000 0.000 0.000 0.007 0.000
Sum up 0.319 0.231 0.283 0.423 0.056 0.257 0.316 0.220 0.262 0.198 0.283 0.614 0.221 0.349 0.274 0.290 0.316 0.067 0.339 0.266 0.462 0.264 0.269 0.368
(B) Cancer
AATF Apoptosis
antagonizing
transcript. factor
17q11.2-q12 0.003 0.007 0.012 0.008 0.022 0.011 0.004 0.003 0.007 0.013 0.008 0.007 0.016 0.011 0.004 0.000 0.004 0.005 0.018 0.001 0.016 0.006 0.009 0.008
APAF1 Apoptotic
peptidase
activating factor
12q23 0.000 0.000 0.001 0.000 0.000 0.002 0.002 0.001 0.001 0.001 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.007 0.001
ATM Ataxia
telangiectasia
mutated
11q22-q23 0.000 0.003 0.002 0.000 0.000 0.005 0.004 0.003 0.000 0.002 0.007 0.015 0.000 0.002 0.000 0.000 0.000 0.001 0.005 0.006 0.002 0.002 0.000 0.006
ATR Ataxia
telangiectasia
and Rad3 related
3q22-q24 0.007 0.000 0.001 0.000 0.002 0.007 0.004 0.011 0.000 0.003 0.002 0.007 0.000 0.007 0.000 0.000 0.000 0.001 0.000 0.007 0.005 0.006 0.005 0.004
BAK1 BCL2-antagonist/
killer 1
6p21.3 0.002 0.007 0.004 0.003 0.007 0.003 0.000 0.000 0.004 0.002 0.002 0.004 0.009 0.001 0.000 0.000 0.003 0.001 0.000 0.004 0.004 0.008 0.005 0.010
BAX BCL2-associated
X protein
19q13.3-q13.4 0.002 0.000 0.001 0.000 0.000 0.001 0.002 0.040 0.000 0.002 0.003 0.000 0.002 0.001 0.000 0.000 0.000 0.003 0.003 0.000 0.001 0.000 0.001 0.002
BCL2 B-cell CLL/
lymphoma 2
18q21.33|18q21.3 0.002 0.003 0.003 0.005 0.000 0.001 0.004 0.004 0.004 0.000 0.008 0.018 0.022 0.013 0.004 0.000 0.016 0.001 0.003 0.003 0.002 0.005 0.016 0.001
BID BH3 interacting
domain death
agonist
22q11.1 0.015 0.007 0.008 0.003 0.004 0.005 0.004 0.001 0.003 0.004 0.001 0.007 0.000 0.001 0.000 0.000 0.001 0.011 0.000 0.003 0.006 0.000 0.002 0.004
BRCA1 Breast cancer 1,
early onset
17q21 0.000 0.000 0.003 0.000 0.011 0.003 0.004 0.001 0.002 0.007 0.003 0.004 0.004 0.002 0.000 0.000 0.003 0.000 0.003 0.003 0.014 0.003 0.007 0.004
BRCA2 Breast cancer 2,
early onset
13q12.3 0.002 0.003 0.000 0.000 0.000 0.003 0.004 0.001 0.003 0.000 0.001 0.018 0.000 0.004 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.004 0.000
CASP2 Caspase 2 7q34-q35 0.005 0.003 0.002 0.008 0.004 0.004 0.000 0.010 0.002 0.001 0.002 0.007 0.000 0.006 0.000 0.000 0.006 0.001 0.003 0.000 0.006 0.000 0.011 0.004
CASP9 Caspase 9 1p36.3-p36.1 0.002 0.000 0.007 0.000 0.020 0.003 0.002 0.003 0.004 0.003 0.005 0.000 0.013 0.004 0.014 0.000 0.002 0.003 0.003 0.001 0.000 0.002 0.003 0.005
CCNE2 Cyclin E2 8q22.1 0.002 0.010 0.002 0.000 0.004 0.001 0.000 0.001 0.000 0.000 0.002 0.004 0.000 0.003 0.000 0.000 0.002 0.001 0.000 0.003 0.002 0.000 0.007 0.000
CCNG1 Cyclin G1 5q32-q34 0.017 0.045 0.011 0.005 0.020 0.014 0.036 0.002 0.012 0.031 0.011 0.025 0.013 0.019 0.011 0.000 0.007 0.003 0.060 0.007 0.006 0.003 0.025 0.023
CCNG2 Cyclin G2 4q21.1 0.007 0.000 0.003 0.013 0.004 0.003 0.004 0.002 0.003 0.004 0.002 0.007 0.002 0.003 0.000 0.000 0.001 0.000 0.005 0.009 0.002 0.002 0.002 0.008
(continued on next page)
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Table 1 (continued)
Gene name Description Cytogenetic
location
Bone Bone
marrow
Brain Cartilage Cervix Colon Eye Head and
neck
Kidney Liver Lung Lymph
node
Lympho-
reticular
Mammary
gland
Muscle Nervous
tissue
Ovary Pancreas Placenta Prostate Skin Stomach Testis Uterus
CDC14A CDC14 cell
divis. cycle 14
homolog A
1p21 0.003 0.000 0.002 0.003 0.000 0.001 0.000 0.001 0.000 0.000 0.001 0.000 0.000 0.001 0.004 0.000 0.000 0.001 0.000 0.000 0.000 0.002 0.000 0.002
CDC2 Cell division
cycle 2, G1 to S
and G2 to M
10q21.1 0.007 0.010 0.003 0.008 0.002 0.005 0.006 0.000 0.004 0.003 0.003 0.007 0.002 0.021 0.004 0.000 0.004 0.003 0.008 0.003 0.003 0.003 0.007 0.011
CDC25A Cell division
cycle 25A
3p21 0.002 0.000 0.001 0.000 0.004 0.002 0.013 0.000 0.001 0.002 0.001 0.000 0.025 0.001 0.021 0.000 0.002 0.004 0.005 0.003 0.003 0.005 0.005 0.004
CDC25C Cell division
cycle 25C
5q31 0.009 0.000 0.003 0.000 0.002 0.005 0.000 0.001 0.000 0.004 0.001 0.004 0.000 0.003 0.000 0.000 0.001 0.001 0.003 0.000 0.002 0.000 0.006 0.014
CDK4 Cyclin-dependent
kinase 4
12q14 0.015 0.003 0.042 0.011 0.065 0.022 0.015 0.005 0.023 0.028 0.025 0.000 0.045 0.031 0.659 0.000 0.045 0.027 0.045 0.016 0.055 0.005 0.018 0.036
CDK7 Cyclin-dependent
kinase 7
5q12.1 0.012 0.000 0.001 0.016 0.016 0.003 0.002 0.004 0.004 0.002 0.004 0.011 0.002 0.013 0.000 0.000 0.000 0.000 0.015 0.000 0.003 0.005 0.002 0.007
CDKN1A/P21 Cyclin-dependent
kinase inhibitor 1A
(p21, Cip1)
6p21.2 0.009 0.021 0.022 0.048 0.031 0.014 0.073 0.008 0.022 0.019 0.116 0.025 0.007 0.010 0.032 0.000 0.008 0.036 0.023 0.013 0.022 0.040 0.011 0.018
CDKN2A interleukin 6
(interferon, beta 2)
9p21 0.003 0.000 0.011 0.003 0.022 0.009 0.000 0.001 0.001 0.003 0.004 0.015 0.009 0.008 0.000 0.000 0.011 0.004 0.008 0.013 0.006 0.002 0.000 0.019
CHEK1 CHK1 checkpoint
homolog
(S. pombe)
11q24-q24 0.002 0.007 0.008 0.003 0.018 0.004 0.004 0.002 0.001 0.008 0.001 0.007 0.007 0.003 0.021 0.000 0.000 0.003 0.003 0.003 0.001 0.002 0.008 0.004
CHEK2/RAD53 CHK2 checkpoint
homolog
(S. pombe)
22q11|22q12.1 0.000 0.010 0.002 0.003 0.013 0.002 0.004 0.000 0.001 0.000 0.002 0.000 0.002 0.006 0.011 0.000 0.003 0.000 0.000 0.000 0.001 0.000 0.001 0.014
CSPG2/VCAN Versican 5q14.3 0.003 0.003 0.018 0.040 0.000 0.012 0.002 0.027 0.014 0.003 0.004 0.000 0.000 0.000 0.004 0.000 0.006 0.027 0.000 0.007 0.001 0.017 0.016 0.006
CX3CL1 Chemokine
(C-X3-C motif)
ligand 1
16q13 0.000 0.000 0.008 0.008 0.000 0.002 0.002 0.000 0.008 0.002 0.004 0.000 0.000 0.001 0.000 0.000 0.000 0.001 0.003 0.001 0.001 0.002 0.001 0.004
DAPK1 Death-associated
protein kinase 1
9q34.1 0.002 0.000 0.006 0.016 0.000 0.003 0.002 0.000 0.010 0.007 0.005 0.000 0.000 0.002 0.007 0.000 0.003 0.001 0.013 0.000 0.002 0.005 0.001 0.006
DAXX Death-associated
protein 6
6p21.3 0.007 0.014 0.014 0.019 0.004 0.007 0.026 0.000 0.010 0.011 0.016 0.007 0.009 0.004 0.000 0.000 0.011 0.008 0.008 0.000 0.010 0.013 0.010 0.013
DDR1 Discoidin domain
receptor family,
member 1
6p21.3 0.000 0.000 0.002 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.000 0.007 0.000 0.000 0.000 0.000
E2F1 APBA2BP, Amyloid
beta (A4) precursor
20q11.22 0.012 0.000 0.013 0.005 0.045 0.008 0.009 0.000 0.003 0.005 0.011 0.011 0.016 0.009 0.007 0.000 0.014 0.023 0.010 0.010 0.011 0.013 0.006 0.009
E2F3 E2F transcription
factor 3
6p22 0.007 0.007 0.002 0.000 0.007 0.007 0.002 0.002 0.003 0.001 0.001 0.004 0.002 0.004 0.011 0.000 0.001 0.001 0.000 0.003 0.007 0.003 0.004 0.001
ERK/EPHB2 EPHB2, EPH
receptor B2
1p36.1-p35 0.009 0.000 0.008 0.003 0.000 0.026 0.002 0.002 0.005 0.002 0.007 0.000 0.000 0.004 0.007 0.000 0.007 0.001 0.000 0.000 0.001 0.006 0.000 0.021
FADD Fas (TNFRSF6)-assoc.
via death domain
11q13.3 0.009 0.000 0.006 0.003 0.013 0.006 0.009 0.006 0.009 0.007 0.011 0.007 0.009 0.009 0.000 0.000 0.005 0.030 0.010 0.001 0.014 0.003 0.005 0.006
FANCA Fanconi anemia,
complement. group A
16q24.3 0.010 0.000 0.003 0.000 0.031 0.015 0.009 0.001 0.003 0.008 0.006 0.004 0.027 0.005 0.000 0.000 0.003 0.001 0.005 0.004 0.002 0.014 0.004 0.009
GADD45A Growth arrest/DNA-
damage-inducible
1p31.2-p31.1 0.010 0.000 0.004 0.000 0.004 0.004 0.006 0.001 0.003 0.002 0.002 0.000 0.002 0.002 0.007 0.000 0.000 0.008 0.000 0.001 0.000 0.003 0.002 0.006
HDAC1 Histone deacetylase 1 1p34 0.022 0.007 0.009 0.019 0.011 0.037 0.004 0.118 0.020 0.007 0.014 0.011 0.058 0.091 0.007 0.000 0.016 0.032 0.010 0.018 0.014 0.336 0.012 0.026
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IL6 Interleukin 6
(interferon, beta 2)
7p21 0.002 0.000 0.001 0.030 0.002 0.001 0.000 0.000 0.004 0.000 0.006 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000
JUN V-jun sarc. virus 17
oncogene homolog
1p32-p31 0.009 0.003 0.023 0.019 0.011 0.021 0.004 0.003 0.019 0.005 0.026 0.004 0.000 0.008 0.011 0.000 0.028 0.012 0.000 0.026 0.008 0.010 0.005 0.029
KRAS V-Ki-ras2 rat sarc.
oncogene homolog
12p12.1 0.005 0.010 0.000 0.011 0.007 0.006 0.000 0.007 0.003 0.002 0.004 0.004 0.002 0.014 0.004 0.000 0.019 0.000 0.008 0.001 0.007 0.003 0.015 0.004
LIG4 Ligase IV, DNA,
ATP-dependent
13q33-q34 0.002 0.000 0.000 0.000 0.000 0.001 0.000 0.002 0.001 0.000 0.000 0.004 0.000 0.003 0.000 0.000 0.000 0.001 0.000 0.000 0.002 0.000 0.002 0.001
MDM2 Mdm2/p53 binding
protein
12q14.3-q15 0.000 0.000 0.000 0.000 0.002 0.008 0.004 0.004 0.000 0.002 0.000 0.000 0.000 0.003 0.014 0.000 0.001 0.000 0.013 0.000 0.000 0.002 0.002 0.002
MDM4 Mdm4/p53 binding
protein
1q32 0.002 0.007 0.004 0.005 0.000 0.009 0.002 0.015 0.005 0.003 0.004 0.015 0.000 0.010 0.000 0.000 0.004 0.000 0.000 0.001 0.003 0.003 0.002 0.008
MSH2 MutS homolog 2
nonpolyposis type 1
2p22-p21 0.002 0.007 0.001 0.005 0.002 0.006 0.015 0.004 0.004 0.011 0.002 0.004 0.007 0.001 0.007 0.000 0.002 0.000 0.005 0.001 0.007 0.003 0.040 0.004
MYC V-myc
myelocytomatosis
homolog
8q24.12-q24.13 0.007 0.100 0.008 0.011 0.018 0.016 0.000 0.010 0.005 0.006 0.006 0.011 0.018 0.005 0.004 0.000 0.007 0.003 0.010 0.015 0.004 0.017 0.007 0.009
P300/
EP300
EP300, E1A binding
protein p300
22q13.2 0.002 0.000 0.008 0.005 0.002 0.012 0.013 0.016 0.003 0.008 0.006 0.011 0.002 0.015 0.000 0.000 0.002 0.001 0.000 0.001 0.005 0.006 0.002 0.009
P38/
MAPK1
MAPK1, Mitogen-
activated prot. Kinase 1
22q11.2|22q11.21 0.022 0.014 0.012 0.019 0.013 0.016 0.009 0.059 0.007 0.014 0.009 0.029 0.000 0.033 0.004 0.000 0.014 0.019 0.003 0.016 0.006 0.013 0.027 0.015
PCAF P300/CBP-associated
factor
3p24 0.002 0.000 0.010 0.013 0.000 0.001 0.000 0.003 0.005 0.001 0.002 0.000 0.000 0.004 0.000 0.000 0.002 0.003 0.005 0.000 0.004 0.005 0.000 0.002
RB1 Retinoblastoma 1 13q14.2 0.005 0.007 0.004 0.003 0.002 0.004 0.002 0.012 0.008 0.005 0.001 0.004 0.002 0.009 0.004 0.000 0.002 0.000 0.005 0.006 0.005 0.000 0.008 0.009
REF3L REV3-like, catal. subun.
of DNA pol zeta
6q21 0.000 0.007 0.002 0.005 0.002 0.005 0.004 0.003 0.007 0.001 0.002 0.004 0.002 0.002 0.000 0.000 0.005 0.000 0.000 0.007 0.002 0.006 0.005 0.007
SHC1 SHC (Src homol. 2
transforming prot. 1
1q21 0.014 0.003 0.033 0.013 0.029 0.005 0.013 0.044 0.013 0.020 0.026 0.015 0.002 0.024 0.018 0.000 0.004 0.058 0.028 0.035 0.022 0.006 0.036 0.023
SIRT1 Sirtuin 1 10q21.3 0.002 0.000 0.000 0.000 0.002 0.002 0.002 0.001 0.000 0.001 0.001 0.011 0.002 0.003 0.000 0.000 0.000 0.001 0.003 0.009 0.001 0.002 0.005 0.002
STAT1 Sign. Transduc.+activ.
of transcript. 1
2q32.2 0.012 0.014 0.006 0.011 0.016 0.016 0.004 0.014 0.028 0.023 0.006 0.025 0.004 0.013 0.004 0.000 0.012 0.015 0.010 0.007 0.029 0.094 0.021 0.066
STAT5A Sign. Transduc.+activ.
of transcript.5A
17q11.2 0.009 0.000 0.002 0.016 0.009 0.006 0.000 0.000 0.002 0.006 0.002 0.044 0.000 0.001 0.000 0.000 0.002 0.005 0.000 0.001 0.000 0.008 0.002 0.002
TNF TNF
(superfamily, member 2)
6p21.3 0.000 0.000 0.000 0.003 0.000 0.001 0.000 0.000 0.000 0.000 0.001 0.022 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
TP53 Tumor protein p53
(Li-Fraumeni)
17p13.1 0.005 0.000 0.014 0.000 0.011 0.016 0.004 0.049 0.012 0.009 0.008 0.029 0.013 0.028 0.004 0.000 0.007 0.001 0.010 0.022 0.002 0.021 0.021 0.014
TP53BP2 Tumor protein p53
binding protein, 2
1q42.1 0.003 0.000 0.003 0.005 0.000 0.002 0.000 0.005 0.003 0.003 0.003 0.011 0.000 0.003 0.004 0.000 0.002 0.000 0.003 0.003 0.002 0.003 0.010 0.004
TP73 Tumor protein p73 1p36.3 0.000 0.000 0.000 0.000 0.000 0.001 0.004 0.005 0.000 0.000 0.002 0.000 0.000 0.001 0.014 0.000 0.000 0.001 0.008 0.000 0.000 0.000 0.000 0.001
TP73L TP73L, Tumor
protein p73-like
3q28 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.071 0.000 0.000 0.001 0.004 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.006 0.000 0.000 0.001
TRADD TNFRSF1A-
associated via
death domain
16q22 0.002 0.000 0.003 0.000 0.000 0.005 0.000 0.001 0.007 0.002 0.009 0.000 0.002 0.004 0.000 0.000 0.002 0.004 0.000 0.000 0.001 0.000 0.000 0.001
WRN Werner syndrome 8p12-p11.2 0.003 0.003 0.000 0.000 0.002 0.001 0.000 0.004 0.001 0.000 0.001 0.000 0.000 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.002 0.001 0.003
WT1 Wilms tumor 1 11p13 0.003 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.001 0.000 0.000 0.006 0.001 0.000 0.000 0.000 0.000 0.001 0.002
XRCC4 XRCC4 DNA
repair protein
5q13-q14 0.000 0.021 0.002 0.000 0.000 0.001 0.026 0.001 0.000 0.002 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.003 0.000 0.004 0.003 0.002 0.003 0.003
Sum up 0.328 0.372 0.391 0.427 0.526 0.421 0.374 0.591 0.333 0.319 0.423 0.482 0.365 0.498 0.923 0.000 0.312 0.375 0.374 0.313 0.345 0.720 0.440 0.537
The columns give the following information (from left to right): short name of the gene, gene description, expression for 24 cancers.
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668 B. Altenberg et al. / Genomics 90 (2007) 661–673which there is no column indicated, no corresponding data are
available in dbEST.
In normal tissue, the expression levels of TP53 range from
0.033 in cartilage to 0.001 in liver, i.e., over the 24 tissues
TP53 expression varies by a factor of 33. Also the effects of
cancer are very different. In cervix, ovary, skin, and stomach
cancer TP53 is down regulated while it is up regulated in
other cancers by up to a factor of 25 in head and neck cancers.
Thus, the expression levels of TP53 and the tested 63 gene
products of related pathways do not show any consistent
trend.
The situation changes dramatically when 63 TP53-related
genes are analyzed. Fig. 2 shows, for the example of normal
bone and ovary tissues, an interesting and consistently observed
principle. The columns in Fig. 2, which represent the sums of
the expression levels of the 63 genes in two tissues as different
as bone and ovary, have similar heights, i.e., their cumulated
expression levels are similar, despite the fact that their
compositions, i.e., the contributions of individual genes, are
very different. For example, in bone, CDKN1A/P21 (dotted
slices) has an expression level sixfold that in ovary. This
difference is compensated for by decreased expression levels of
other genes. Such a behavior defines the system of 63 p53-
interacting genes as a candidate for a functional gene ensemble
as mentioned in the introduction.
Fig. 3 shows that the observation of Fig. 2 is not specific for
these two cancers but can be more generalized. Five tissues are
shown, now in comparison with their corresponding cancers.Fig. 2. Cumulated, nonweighted expression levels of all 63 genes for normal bone an
levels are similar. However, individual genes contribute very differently to the sum.
sixfold more in bone than in ovary (fourth from bottom).The tissues have been selected because their cumulated
expression levels in cancer are similar to or only slightly higher
than those of their normal tissues. Again, similar cumulated
levels are achieved with very different contributions of single
genes.
Fig. 4 gives the corresponding data for all tissues. The
columns are plotted as pairs, with the normal tissue on the left
and the corresponding cancer tissue on the right. Again, the
compositions of the different columns vary vastly. All
columns, except those of normal cervix and pancreas tissue
and those of muscle and stomach cancer, have heights
between 0.2 and 0.6, i.e., the variation of a factor of up to 33
for individual genes has been reduced to a factor of 3. A
major part of this reduction just reflects the better statistics
upon averaging. However, since data for normal and cancer
tissue are treated identically, a remaining difference in the
mean value and the variation can be isolated from these data
that reflects a real biomedical effect.
When the cumulated expression levels in cancer are plotted
as a function of the expression levels in normal tissues, a linear
regression yields a straight line with a slope close to zero; thus,
cumulated expression levels in cancer are independent of those
in normal tissue.
The message of Fig. 5 is that there is a tendency, in cancer, to
unify the cumulated expression levels. Note that this statement
still holds when the two extreme cases of muscle cancer and
cancer of the nervous tissue (either one of them or both) are
removed from the regression analysis.d ovary tissue. Both columns are similar in height, i.e., the cumulated expression
For example, CDKN1A/P21 (white dotted slice, fifth from bottom) contributes
Fig. 3. Cumulated, nonweighted expression levels for bone, cartilage, ovary, placenta, and prostate together with their cancers.
669B. Altenberg et al. / Genomics 90 (2007) 661–673The discussion so far has treated each tissue separately.
While such an approach is sufficient to get some plausible
results, it treats a given gene in different tissues as a completelyFig. 4. Cumulated, nonweighted expression levels in all 24 tissues for normalindependent quantity. However, genes of, for example, a
classical pathway should behave similarly in different tissues,
i.e., they are not really independent. Therefore, all 63 genes intissue and cancer with the single genes as slices in the cumulated column.
Fig. 5. Cumulated, nonweighted expression levels sorted according to the corresponding value in normal tissue. Cervix, with the lowest expression in normal tissue, is
in the leftmost position. The solid line is the regression line.
Table 2
Weights for the 63 genes calculated for the data of Table 1 to obtain a robust
statistical classifier
AATF −26.6 CDKN1A/P21 −4.6 MDM4 37.8
APAF1 129.9 CDKN2A −79.3 MSH2 −31.7
ATM 22.6 CHEK1 −88.7 MYC 0.4
ATR −5.3 CHEK2/RAD53 196.4 P300 13.8
BAK1 7.3 CSPG2 −14.6 P38/MAPK1 1.3
BAX −21.5 CX3CL1 43.5 PCAF 56.8
BCL2 27.2 DAPK1 7.5 RB1 −40.7
BID −43.0 DAXX 29.7 REF3L −8.1
BRCA1 30.8 DDR1 82.0 SHC1 24.6
BRCA2 −26.7 E2F1 16.0 SIRT1 118.7
CASP2 14.7 E2F3 93.5 STAT1 −0.2
CASP9 −28.2 ERK/EPHB2 −23.9 STAT5A 25.8
CCNE2 −80.1 FADD −54.6 TNF −46.4
CCNG1 13.0 FANCA 69.8 TP53 −28.6
CCNG2 −34.9 GADD45A 64.5 TP53BP2 55.3
CDC14A 182.8 HDAC1 −4.3 TP63 16.2
CDC2 −13.2 IL6 −10.8 TP73 88.7
CDC25A −55.5 JUN −40.5 TRADD −26.0
CDC25C −79.5 KRAS2 −15.6 WRN −109.8
CDK4 −3.9 LIG4 12.7 WT1 65.2
CDK7 −87.0 MDM2 1.7 XRCC4 −96.3
With these weights, all 24 normal tissues, without exception, have a weighted
sum of +1; those of all 24 cancer tissues, without exception, have a sum of −1.
When we apply this classifier to 13 additional tissues and their cancers, which
were, due to poor data quality, not included into the construction of the classifier,
19/26 cases are correctly classified. Of the remaining 7 cases (4 normal and 3
cancer tissues), 5 have an exceedingly high expression of the oncogene JUN. If
one corrects for this fact, only 2 cases are finally predicted incorrectly.
670 B. Altenberg et al. / Genomics 90 (2007) 661–673all 24 normal tissues and all 24 cancer tissues have to be
regarded as one large ensemble. A first hint comes from Fig. 5.
There, for most cancers, the cumulated gene expression is
higher for cancer than for normal tissue, but for some tissues the
situation is reverse. Therefore, cumulated gene expression does
not completely qualify as a statistical classifier.
Weighted sums, instead of cumulated gene expressions, are
better suited to separate the values for normal and cancer tissue.
Regarding the weights as variables, we define a system of 48
linear equations, one for each tissue, the weighted sum
being +1 for normal and −1 for cancer tissue, respectively.
As described under Materials and methods, the system can
be solved for the weights. In fact, there is a 15-dimensional
solution space. In Table 2, we present only one extreme
solution for the weights, which have minimal moduli with
respect to a certain minimality criterion (Materials and
methods).
It is difficult to characterize the statistical significance of this
linear classifier, as it should incorporate the significance levels
of the gene expression levels themselves, which are not
precisely known. Instead, we compute the maximal simulta-
neous deviation tolerance for all gene expression levels. For the
given weighted sum a simultaneous deviation of 5.18% from all
norm expression levels is tolerable and will still give a true
positive. If all deviations are higher and have the right sign, a
false positive will result. But as the particular deviations need to
have the same sign (opposite sign, respectively) for cancer
(normal, respectively) tissue as the associated weight, this
particular event has a probability of less than 2−63 to give a false
positive. To describe the statistical relevance completely, all
possible deviation combinations would have to be taken into
account, of course.
So, in practice, individual deviations of gene expression
levels can be much higher than 5.18%, as others will be lower or
point to the opposite direction. Altogether, the prediction of theweighted sum is “normal tissue” for a value larger than −0.0558
and “cancer tissue” for a value smaller than −0.0558.
Discussion
The practical use of the classifier defined in this work is that
for a sample from an arbitrary test tissue, for example from an
Table 3
A typical output obtained from dbEST/Virtual Northern for TP53
Tissue ESTs normal ESTs cancer ESTs p
All tissues 286/3,383,090 347/2,493,099 0
Adrenal cortex 1/10,398
Adrenal medulla 0/563
Bone 0/16,327 3/58,481 0.32
Bone marrow 0/15,569 0/29,006
Brain 46/281,828 29/205,624 0.27
Cartilage 5/15,115 0/37,250 0.02
Cerebellum 1/85,605 0/0
Cerebrum 11/201,756 1/3,409 0.3
Cervix 1/3,587 5/44,447 0.37
Colon 3/28,048 27/170,009 0.27
Ear 0/16,691
Embryonic tissue 18/206,103
Endocrine 3/16,599 0/3,196 0.36
Esophagus 0/87 2/16,534 0.5
Eye 2/123,703 2/46,738 0.3
Gastrointestinal tract 6/27,888 1/12,896 0.24
Genitourinary 5/8,868 5/27,005 0.11
Head and neck 1/42,364 50/101,855 0
Heart 2/76,379
Kidney 3/105,997 11/91,306 0.02
Limb
Liver 1/108,116 9/100,640 0.02
Lung 11/132,698 14/178,796 0.46
Lymph node 4/67,732 8/27,585 0.02
Lymphoreticular 0/18,077 6/44,599 0.15
Mammary gland 16/55,033 32/115,515 0.45
Muscle 1/81,895 1/28,054 0.38
Nervous 14/230,648 0/0
Ovary 2/11,727 7/94,538 0.29
Pancreas 0/7,427 1/75,431 0.47
Pancreatic islet 2/101,122 0/30,585 0.37
Parathyroid 0/20,837
Peripheral nervous system 0/15,784 0/908
Pineal gland 0/6,855
Pituitary gland 0/13,819 0/1,576
Placenta 11/254,569 4/39,851 0.17
Pooled tissue 6/293,822 0/0
Prostate 11/84,150 15/68,285 0.12
Retina 2/33,149
Salivary gland 1/2,589 1/10,358 0.35
Skin 5/53,904 2/125,563 0.06
Spleen 20/52,423
Stem cell
Stomach 9/28,058 13/62,881 0.21
Synovium 0/259 0/1,875
Testis 14/146,275 26/121,114 0.01
Thymus J1/4,775 0/179 0.49
Thyroid 4/13,493 6/38,730 0.25
Uncharacterized tissue 24/162,630 46/306,017 0.46
Uterus 0/38,584 19/140,465 0.02
Vascular 20/45,617
White blood cells
Whole body 0/45,346
For a set of 51 tissues (plus four pooled data sets) values for expression in
normal tissue and in the corresponding tumor tissue are given (for details see
text). The p values in the column on the right indicate the statistical quality of the
data for each cancer. This value has to be taken into account when a single gene
for a single tissue is discussed; only data with p values b0.05 are completely
reliable. In the discussion of whole ensembles of data, larger p values are
acceptable.
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decided, on the basis of the expressions of the selected 63 genes
and with the determined 63 weight factors, if it is cancerous
(then its weighted sum should be close to −1) or normal (then its
weighted sum should be close to +1). Different subtypes of
cancers, different tumor stages, possible ethnic variability, and
epidemiological aspects can then be determined as deviations of
details in the set of 63 TP53-related genes.
A finding of more principal importance is that despite gross
differences in the expression of single genes the cumulated
expression of the 63 varies only by a factor of 3 in all 24 healthy
and cancer tissues, with very few exceptions. Such a statement
would be almost trivial if the ensemble of investigated genes
were the whole set of genes in a cell, since on the one hand, one
would expect that the expression of individual genes is
massively dysregulated to make a cell cancerous, but on the
other hand, the cumulated expression and use of all genes in a
cell cannot be grossly different from that of a normal cell, since
even in aggressive cancer cells the metabolism as a whole is
increased at most a few fold. That such an observation is made
already at the level of an ensemble of only 63 genes, i.e., less
than 1% of all genes in a cell, is remarkable, though it will
require additional experiments to understand this in molecular
detail.
There may be the objection that the effects we have seen are
just due to an improved statistics upon “averaging” over many
genes. This is, however, not the case: With 63 genes randomly
selected from genes of stress response, we find no increase in
the average cumulative expression between normal and cancer
tissue (even a slight, though nonsignificant decrease) and no
significant narrowing of the relative standard deviation over the
24 tissues. Thus, an increase in overall expression and a
narrowing of expression levels are real.
Materials and methods
Sixty-three genes were selected from the pathways involving the TP53
tumor-suppressor gene. They are located up- or downstream of TP53 and were
selected from the following pathways according to the KEGG (www.genome.jp/
kegg): ko04310, ko04210, ko05030, and ko05040. We have not only chosen
genes that are direct binding partners of p53, but have included further genes
(mostly tumor-suppressor or oncogenes of the pathways MAP kinase signaling,
cell cycle, and apoptosis and transcription factors).
Expression data for these genes as well as the classification of tissues have
been obtained via the Virtual Northern function of NIH's database dbEST
[14,15,20]. This database searches the literature for data from DNA or
oligonucleotide chip experiments, normalizes them, and lists the results gene by
gene for a set of 51 tissues (plus three pooled values). Table 3 gives a typical
output, which one can obtain via http://cgap.nci.nih.gov/Genes/GeneFinder for
the example of the TP53 gene.
The data in this table are already preevaluated and imply sophisticated
statistical considerations, which have been accepted by a wide range of users of
this database as being adequate for describing gene expression in normal and in
cancer tissue [14,20]. For example, to get an idea whether the statistical quality
of the data is sufficient to state overexpression in cancer, let us first assume that
the Gaussian statistics is valid. If one finds 16 counts for cancer, the Gaussian
error is √16=4. If for normal tissue 9±3 counts are found, the ratio may be
formally calculated as 1.77. The calculated error of the difference is then 7
counts, as the measured difference. For some applications one may accept this as
“just significant.” One should, however, realize that, according to the Gaussian
theory, approximately 32% of all ratios in that case indicate “overexpression,”
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ratio (=1.77) had been obtained with 160±√160 and 90± √90 counts, the error
of the difference would be 12.7+9.5=20.2 counts at a measured difference of 60
counts. Here, the risk of giving a false statement “overexpression” is much
lower, a few percent. Also, low count data allow, in contrast to the first example
above, reliable statements, if the ratio is high. For example, for 25±5 and 9±3
the ratio is 2.8, its calculated error difference of 8 at a measured difference of 16
is 2 standard deviations. The probability that a statement with more than 2
standard deviations is obtained by chance is approximately 5% or 1:20, i.e., only
in every 20th data set would a wrong statement on overexpression result for
purely statistical reasons. The database dbEST gives these percentages, divided
by 100, as p values, for each data pair “cancer versus normal,” and allows also
for non-Gaussian statistics where necessary, for example, at count rates below
10, where Poisson statistics replaces Gaussian statistics. These measures of
statistical quality can also be applied to any other pair of data, for example, when
results have to be compared between two (or pair-wise between many) tissues.
Currently, the database contains information on the expression of some 4
million genes or ESTs. For a given tissue, typically some 10,000 to 100,000
pieces of data are available. To understand this in more detail, one may imagine a
large chip for each tissue with a number of hybridization signals for each gene or
EST. The number “h” of hybridization signals (typically a few up to a few tens)
divided by the number “t” of hybridization targets on the chip is used as the
expression level, usually a number much smaller than 1. Note that the way to
evaluate data given by dbEST is not a result of the present work, but essentially
given by the providers of the database at NIH. With the remarks above we just
try to make the complex dbEST data comprehensible to a reader who does not
wish to go into the details of the database (for additional details see also [3,8]).
For example, in the case of colon cancer, Table 3 gives h=27 hybridization
signals of p53 on t=170,009 targets, i.e., h/t=0.000159. Since we are interested
only in relative expression levels, we multiply h/t by 100 for convenience, i.e.,
the value 0.0159 will be used in Table 1.
Once one has complete expression data for many genes andmany tissues, one
may attempt to get a quantitative measure to distinguish between normal and
cancer tissue. Such a measure is called a statistical classifier. In a quite general
sense, a classifier is the result of a mathematical procedure, which can be defined
more or less arbitrarily. In our case it is just a suitably chosen sum of expression
levels. In the first part of the Results we used the direct (nonweighted) sums of the
expression levels of the 63 genes to discuss differences and similarities of gene
expression in cancer and normal tissues. This explained a few basic results of our
investigation but would not be suitable as a classifier. Therefore, we used
weighted sums of the gene expression levels aji for normal and cancer tissues.We
looked for 63 a priori unknown weights gi as the solution of a system of 48 linear
equations. There the expression levels, aji for the 63 genes in the 48 (=24 normal
+24 cancer) tissues as they are listed in Table 1, are the coefficients of the
corresponding equation system. To construct the classifier, we have used just the
24 tissues and their cancers, which are discussed throughout this paper. We go,
however, a step further and apply that classifier to 13 additional tissues, which
has a fundamental drawback: since they are in the literature less well investigated
tissues, the statistical quality of their data is poor and would usually not be
suitable for distinction between normal and cancer tissue. Despite that, otherwise,
serious problem, a result of our study is that, with the classifier obtained here, it is
possible to classify tissues even when the statistical quality of the data is poor.
We define the weighted sums for all normal tissues to be bj=1 for normal
tissue and bj=−1 for cancer tissue, resulting in the equation
X
ajigi ¼ bjði ¼ 1; N ; 63; j ¼ 1; N ; 48Þ:
In the first part of the Results, in which we discuss “cumulated expression
levels,” all gi are set to 1, i.e., all expression levels will have the sameweight of 1.
A disadvantage of this nonweighted approach is that genes with a low expression
level are underestimated in their importance. In the second part of the Results the
weights are different for each gene and thus allow for the relative importance of
each given gene.
“Full pivoting Gauss elimination” [21] showed that the system has maximal
rank yielding a 15 (=63−48)-dimensional solution space. Accordingly, 15
parameters can be chosen freely and the other 48 are “affine” combinations of
these. We chose several objective functions to find optimal solutions in thisparameter space. The solution we present in Table 2 is minimal with respect to
the weighted (weights hi) sum of the 63 squared weights gi. The weights hi here
are calculated as the square roots of the maximum of the associated expression
levels of the respective gene in all tissues. Choosing other weights hi in objective
functions does not alter the character of the minimal solution substantially. The
minimal solution was found by usual weighted least-squares fit routines [22].
To get an impression of the statistical relevance of such an “all tissue”
classifier, we compute the maximal possible derivation of all norm expression
values, such that, if all expression level measurements deviate less than this
value, the prediction “normal” or “cancer” is correct (true positive). For normal
tissue, the value of the weighted sum is decreased if, for positive weights gi, the
expression level is decreased, e.g., by a factor of 1−p. For negative weights gi, it
is increased by a factor of 1+p. For cancer tissue, the respective factors are 1
+p and 1−p, respectively. Equating the maximal deviations for normal and
cancer tissue, we find the maximal tolerable deviation from the norm level in
the case in which all deviations combine in the decreasing (for normal tissue)
or increasing (cancer tissue) direction (worst case analysis). The tolerance
level we find for our example is p=0.0518 or 5.18% and the corresponding
weight sum for the disturbed expression levels is s=−0.0558.
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